These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas. Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371 [TBL] [Abstract][Full Text] [Related]
43. Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma. Traweek RS; Cope BM; Roland CL; Keung EZ; Nassif EF; Erstad DJ Front Oncol; 2022; 12():1006959. PubMed ID: 36439412 [TBL] [Abstract][Full Text] [Related]
44. Diagnostic Utility and Limitations of Immunohistochemistry of p16, CDK4, and MDM2 and Automated Dual-color In Situ Hybridization of MDM2 for the Diagnosis of Challenging Cases of Dedifferentiated Liposarcoma. Kobayashi A; Sakuma T; Fujimoto M; Jimbo N; Hirose T Appl Immunohistochem Mol Morphol; 2019; 27(10):758-763. PubMed ID: 31145104 [TBL] [Abstract][Full Text] [Related]
46. A novel HMGA2::KITLG fusion in a dedifferentiated liposarcoma with amplification of MDM2 and HMGA2. Zhou S; Zhang C; Zhang Z; Hu Y; Zhao L; Hu W; Chen S; Li B; Xiao S Genes Chromosomes Cancer; 2024 Jan; 63(1):e23200. PubMed ID: 37698344 [TBL] [Abstract][Full Text] [Related]
47. MDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma Models. Patt A; Demoret B; Stets C; Bill KL; Smith P; Vijay A; Patterson A; Hays J; Hoang M; Chen JL; Mathé EA Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32759684 [TBL] [Abstract][Full Text] [Related]
48. What Are the Results of Resection of Localized Dedifferentiated Liposarcomas in the Extremities? Nakata E; Kunisada T; Hasei J; Nakahara R; Yanai H; Toji T; Inoue Ct H; Ozaki T Clin Orthop Relat Res; 2020 Nov; 478(11):2550-2561. PubMed ID: 33112583 [TBL] [Abstract][Full Text] [Related]
49. Vanished MDM2 amplification in multiple recurrences of an irradiated poorly differentiated sarcoma with amplified TRIO::TERT fusion gene. Goffinet S; Di Mauro I; Doyen J; Boyer J; Birtwisle-Peyrottes I; Keslair F; Pedeutour F; Dadone-Montaudie B Genes Chromosomes Cancer; 2023 Jun; 62(6):342-352. PubMed ID: 36916207 [TBL] [Abstract][Full Text] [Related]
50. High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: A cytogenomic microarray analysis of 47 cases. Ricciotti RW; Baraff AJ; Jour G; Kyriss M; Wu Y; Liu Y; Li SC; Hoch B; Liu YJ Cancer Genet; 2017 Dec; 218-219():69-80. PubMed ID: 29153098 [TBL] [Abstract][Full Text] [Related]
51. Intraperitoneal dedifferentiated liposarcoma showing MDM2 amplification: case report. Grifasi C; Calogero A; Carlomagno N; Campione S; D'Armiento FP; Renda A World J Surg Oncol; 2013 Nov; 11():305. PubMed ID: 24279301 [TBL] [Abstract][Full Text] [Related]
52. Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery. Keung EZ; Hornick JL; Bertagnolli MM; Baldini EH; Raut CP J Am Coll Surg; 2014 Feb; 218(2):206-17. PubMed ID: 24315890 [TBL] [Abstract][Full Text] [Related]
53. Utility of fluorescence in situ hybridization to detect MDM2 amplification in liposarcomas and their morphological mimics. Kimura H; Dobashi Y; Nojima T; Nakamura H; Yamamoto N; Tsuchiya H; Ikeda H; Sawada-Kitamura S; Oyama T; Ooi A Int J Clin Exp Pathol; 2013; 6(7):1306-16. PubMed ID: 23826411 [TBL] [Abstract][Full Text] [Related]
54. Dedifferentiated liposarcoma with homologous lipoblastic differentiation: expanding the spectrum to include low-grade tumours. Liau JY; Lee JC; Wu CT; Kuo KT; Huang HY; Liang CW Histopathology; 2013 Apr; 62(5):702-10. PubMed ID: 23425231 [TBL] [Abstract][Full Text] [Related]
55. To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma. Weiss MC; Eulo V; Van Tine BA Clin Cancer Res; 2024 Feb; 30(4):649-651. PubMed ID: 38064245 [TBL] [Abstract][Full Text] [Related]
56. MDM2 amplification and fusion gene ss18-ssx in a poorly differentiated synovial sarcoma: A rare but puzzling conjunction. Di Mauro I; Mescam-Mancini L; Chetaille B; Lae M; Pierron G; Dadone-Montaudie B; Bazin A; Bouvier C; Michiels JF; Pedeutour F Neoplasia; 2020 Aug; 22(8):311-321. PubMed ID: 32559641 [TBL] [Abstract][Full Text] [Related]
57. A Proposed Staging System for Improved Prognostication of MDM2-amplified Liposarcoma. Tucci JJ; Dashti NK; Cates JMM Am J Surg Pathol; 2021 Jan; 45(1):101-107. PubMed ID: 32796171 [TBL] [Abstract][Full Text] [Related]
58. Differences in recurrence and survival of extremity liposarcoma subtypes. Vos M; Koseła-Paterczyk H; Rutkowski P; van Leenders GJLH; Normantowicz M; Lecyk A; Sleijfer S; Verhoef C; Grünhagen DJ Eur J Surg Oncol; 2018 Sep; 44(9):1391-1397. PubMed ID: 29673808 [TBL] [Abstract][Full Text] [Related]
59. Therapeutic strategies for locally recurrent and metastatic de-differentiated liposarcoma with herpes simplex virus-thymidine kinase-expressing mesenchymal stromal cells. Lee H; Jo EB; Kim SJ; Yang HM; Kim YM; Sung YC; Park JB; Hong D; Park H; Choi YL; Kim SJ Cytotherapy; 2017 Sep; 19(9):1035-1047. PubMed ID: 28760351 [TBL] [Abstract][Full Text] [Related]
60. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. Aleixo PB; Hartmann AA; Menezes IC; Meurer RT; Oliveira AM J Clin Pathol; 2009 Dec; 62(12):1127-35. PubMed ID: 19946100 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]